InvestorsObserver is giving Recursion Pharmaceuticals Inc (RXRX) an Analyst Rating Rank of 17, meaning RXRX is ranked higher by analysts than 17% of stocks. The average price target for RXRX is $16 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating RXRX a Buy today. Find out what this means to you and get the rest of the rankings on RXRX!